Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01916850 · ClinicalTrials.gov registry record · Phase 1
Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01916850 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT01916850, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of multiple oral doses of LX4211 400 mg and LX4211 800 mg (administered once daily for 10 consecutive days) in healthy subjects.
Interventions
- DRUG LX4211 800 mg
- DRUG LX4211 Placebo
- DRUG LX4211 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01916850
The ClinicalTrials.gov registry entry for NCT01916850 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LX4211 800 mg is the first listed.
NCT01916850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01916850 about?
NCT01916850 is a clinical study titled "Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects". The primary objective of this study is to evaluate the safety and tolerability of multiple oral doses of LX4211 400 mg and LX4211 800 mg (administered once daily for 10 consecutive days) in healthy subjects.
What is the current status of trial NCT01916850?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2013-08.
What interventions are being tested in trial NCT01916850?
The interventions under investigation include: LX4211 800 mg (DRUG), LX4211 Placebo (DRUG), LX4211 400 mg (DRUG).
Who is sponsoring clinical trial NCT01916850?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.